December 2025 - MediaMedic

Summit Dialogue | Professors Zhang Guojun & Michael Gnant: New Frontiers in Neoadjuvant Therapy for HER2-Positive Breast Cancer

By Mourabit Halima 2025.12.31

Editor’s note: For patients with HER2-positive breast cancer, neoadjuvant treatment strategies are rapidly evolving—from traditional dual HER2 blockade to the fast-emerging era of antibody–drug conjugates (ADCs). Recently, Chinese-developed anti-HER2 ADCs…

SABCS China Voice | Professor Wang Biyun: Beware of ER Loss — Study Reveals Poor Prognosis in Patients Converting from ER-Positive to ER-Negative

By Mourabit Halima 2025.12.30

Editor’s Note: Estrogen receptor (ER)–positive breast cancer has long been regarded as a relatively “indolent” subtype. However, during disease progression, a subset of patients experience loss of ER expression, converting…

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Reshape Breast Cancer Neoadjuvant Therapy

By Peng Geng 2025.12.30

Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

SABCS China Voice | Prof. Wang Yongsheng: Ki-67–Guided Precision Strategies and Multi-Omics Insights Redefine Neoadjuvant Breast Cancer Treatment

By Peng Longmei 2025.12.30

Editor’s Note: As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

SABCS China Voice | Professors Yan Min & Lü Huimin: U-BOMB-HER Study Advances Treatment of HER2-Positive Brain Metastases

By Mourabit Halima 2025.12.30

Editor’s Note: In recent years, systemic treatment options for HER2-positive breast cancer brain metastases have made meaningful progress, yet substantial unmet clinical needs remain. At the 2025 San Antonio Breast…

SABCS China Voice | Professor Yan Min’s Team: Post-PERMEATE Study Clarifies Radiotherapy Timing in HER2-Positive Brain Metastases

By Mourabit Halima 2025.12.30

Editor's Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…

ASH Global Perspectives | Prof. Hanny Al-Samkari: Efficacy, Safety, and Dose Optimization of Ianalumab + Eltrombopag in Second-Line ITP

By Peter W. PENG 2025.12.30

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…

ASH Global Perspectives | Professor Jeff Sharman: How Can We Reshape Treatment Strategies for Elderly Patients With DLBCL?

By Peng Longmei 2025.12.30

Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…

ASH Global Perspectives | Prof. Fabio Efficace’s Team: Advances in Patient-Reported Outcomes in Hematology

By Mourabit Halima 2025.12.30

In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…

New Breakthrough in Targeting BAFF Pathway: Ianalumab Significantly Prolongs Time to Treatment Failure in ITP Patients — A Detailed Look at VAYHIT 2

By Mourabit Halima 2025.12.30

At the recently concluded American Society of Hematology (ASH) Annual Meeting in 2025, Dr. Hanny Al-Samkari from Massachusetts General Hospital presented the highly anticipated primary analysis of the VAYHIT 2 study. Presented as a Late-Breaking Abstract (LBA), this global, randomized, double-blind, Phase 3 clinical trial evaluated the efficacy and safety of combining the novel BAFF receptor antagonist Ianalumab with Eltrombopag in patients with primary immune thrombocytopenia (ITP). The results signal a potential paradigm shift for patients who have failed first-line corticosteroid therapy, offering a new avenue for durable disease control.